1.075
0.47%
0.005
Schlusskurs vom Vortag:
$1.07
Offen:
$1.08
24-Stunden-Volumen:
26,644
Relative Volume:
0.14
Marktkapitalisierung:
$35.87M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-13.27M
KGV:
-6.5549
EPS:
-0.164
Netto-Cashflow:
$-7.70M
1W Leistung:
+1.41%
1M Leistung:
+9.69%
6M Leistung:
-26.87%
1J Leistung:
-36.01%
Okyo Pharma Limited Stock (OKYO) Company Profile
Firmenname
Okyo Pharma Limited
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie OKYO mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
OKYO | 1.075 | 35.87M | 0 | -13.27M | -7.70M | -0.164 |
VRTX | 450.01 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 746.02 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 594.70 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 245.85 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 107.66 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Okyo Pharma Limited Aktie (OKYO) Neueste Nachrichten
MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire
OKYO Pharma (LON:OKYO) Trading Down 24.3% – Here’s What Happened - Defense World
OKYO Pharma to present Phase 2 dry eye disease trial data at TFOS conference - Proactive Investors USA
OKYO Pharma Advances in Ocular Treatment Trials - TipRanks
OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference - The Manila Times
OKYO Pharma Limited to Present at International Tear Film & Ocular Surface Society Conference - Marketscreener.com
OKYO Pharma doses first patient in Phase 2 neuropathic corneal pain trialICYMI - Proactive Investors Australia
H.C. Wainwright maintains stock target, buy rating on OKYO Pharma shares - Investing.com India
OKYO Pharma CEO Announces First Dosing in Phase 2 Trial for OK-101 to Treat Neuropathic Corneal Pain - Proactive Investors UK
OKYO Pharma doses first subject in OK-101 Phase II trial for NCP - Clinical Trials Arena
H.C. Wainwright maintains stock target, buy rating on OKYO Pharma shares By Investing.com - Investing.com South Africa
Wainwright sustains Buy rating on OKYO Pharma shares on clinical trial progress - Investing.com
OKYO Pharma launches Phase 2 trial for NCP treatment - Investing.com India
OKYO Pharma commences Phase 2 trial for ocular pain treatment By Investing.com - Investing.com Australia
OKYO Pharma launches Phase 2 trial for NCP treatment By Investing.com - Investing.com Australia
OKYO Pharma shares surge on Phase 2 neuropathic corneal pain trial update - Proactive financial news
OKYO Pharma commences Phase 2 trial for ocular pain treatment - Investing.com India
OKYO Pharma Begins Key Trial for Eye Pain Therapy - TipRanks
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain - GlobeNewswire
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain - GlobeNewswire Inc.
Q2 Earnings Estimate for OKYO Pharma Issued By HC Wainwright - Defense World
H.C. Wainwright maintains Buy rating on OKYO Pharma shares By Investing.com - Investing.com UK
OKYO Pharma Begins Key Phase 2 Trial for Eye Pain Drug - Yahoo Finance
OKYO Pharma begins phase 2 trial for NCP treatment - Investing.com
OKYO Pharma begins phase 2 trial for NCP treatment By Investing.com - Investing.com UK
OKYO Pharma begins Phase 2 trial for neuropathic corneal pain treatment - Proactive Investors USA
OKYO begins patient enrollment for Phase 2 NCP trial By Investing.com - Investing.com Australia
OKYO begins patient enrollment for Phase 2 NCP trial - Investing.com
OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain - GlobeNewswire
OKYO Pharma (NASDAQ:OKYO) Shares Up 3% – What’s Next? - Defense World
Neuropathic Ocular Pain Market Overview: Size, Growth - openPR
Oklo Inc. (OKLO) is looking forward to a strong quarter - SETE News
Understanding OKLO’s book value per share for better investment insights - US Post News
XTX Topco Ltd Purchases 5,759 Shares of OneMain Holdings, Inc. (NYSE:OMF) - Defense World
Multibagger Stock under Rs 20: After stock split, Ok Play allots equities upon warrants conversion - ET Now
Ok Play's board approves allotment of Equity sharesCheck details - India.com
Oklo Inc. (NYSE:OKLO) Forecasted to Post Q3 2024 Earnings of ($0.11) Per Share - MarketBeat
XTX Topco Ltd Acquires Shares of 33,954 Omega Healthcare Investors, Inc. (NYSE:OHI) - Defense World
Traders Buy High Volume of Oklo Call Options (NYSE:OKLO) - MarketBeat
Orkla India eyes public listing after completing restructuring | Company Business News - Mint
Tomohiro Okada named president, director of Universal Ent - GGRAsia
Multibagger Penny Stock Under Rs 20 Surges Over 50 Per Cent From Its 52-Week Low; Board Allots Equity Shares On Conversion Of Warrants To Promoters - Dalal Street Investment Journal
OKYO Pharma (LON:OKYO) Stock Price Down 24.3% - Defense World
Oklo Inc. (OKLO) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
OKYO Pharma executive chairman increases stake - Investing.com
OKYO Pharma executive increases stake in company By Investing.com - Investing.com Australia
OKYO Pharma executive chairman increases stake By Investing.com - Investing.com UK
OKYO Pharma executive increases stake in company - Investing.com
OKYO Pharma Chairman Boosts Stake, Advances Trials - TipRanks
Okyo Pharma announces acquisition of shares by chairman - TipRanks
OKYO Pharma Announces Chairman Acquires Shares - GlobeNewswire
Finanzdaten der Okyo Pharma Limited-Aktie (OKYO)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):